Repository logoGCRIS
  • English
  • Türkçe
  • Русский
Log In
New user? Click here to register. Have you forgotten your password?
Home
Communities
Browse GCRIS
Overview
GCRIS Guide
  1. Home
  2. Browse by Author

Browsing by Author "Ayan, Arif Kuersad"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Article
    Research for a New Imaging Agent: in Vivo Examination of Silymarin Loaded Solid Lipid Nanoparticles Radiolabeled With 99mtc in Rabbits
    (Elsevier, 2024) Eroglu, Hayrettin; Ayan, Arif Kuersad; Yenilmez, Ays
    Silymarin is known to be protective against some diseases such as liver diseases and is used for this purpose. In this study, it is aimed to determine the usability of silymarin loaded solid lipid nanoparticles as a radiopharmaceutical for diagnostic purposes in nuclear medicine. S-SLN was prepared by microemulsion and ultrasonication method. Then analyzed by using SEM images, TGA Analysis, XRD and IR. It was concluded that S-SLN particles were nano -sized according to the LD analysis, spherical and nano -sized according to SEM images, stable against temperature according to TGA analysis, and silymarin was loaded into solid lipid nanoparticles according to XRD and IR. In the second stage of the study, S-SLNs were marked with 99m Tc and in vivo studies were carried out on rabbits by scintigraphic methods. When the images obtained were examined, it was seen that there were involvements in the liver and spleen. According to the results obtained, it is thought that S-SLN labeled with 99m Tc can be a selective imaging agent. It has been concluded that an alternative to 99m Tc-analogues for imaging the liver and spleen may be a novel radiopharmaceutical.
Repository logo
Collections
  • Scopus Collection
  • WoS Collection
  • TrDizin Collection
  • PubMed Collection
About
  • Contact
  • GCRIS
  • Research Ecosystems
  • Feedback
  • OAI-PMH

Powered by Research Ecosystems

  • Privacy policy
  • End User Agreement
  • Feedback